H. Lundbeck A/S

CPSE:HLUN B Stock Report

Market Cap: DKK 43.0b

H. Lundbeck Future Growth

Future criteria checks 0/6

H. Lundbeck's revenue and earnings are forecast to decline at 3.4% and 4.5% per annum respectively. EPS is expected to decline by 3.7% per annum. Return on equity is forecast to be 12.9% in 3 years.

Key information

-4.5%

Earnings growth rate

-3.73%

EPS growth rate

Pharmaceuticals earnings growth10.7%
Revenue growth rate-3.4%
Future return on equity12.88%
Analyst coverage

Good

Last updated08 Jun 2026

Recent future growth updates

Analysis Article • May 15

Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Analysis Article • Feb 07

H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...
Analysis Article • Nov 15

Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...
Analysis Article • Aug 16

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...

Recent updates

Narrative Update • Jun 06

HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple

Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.
Analysis Article • May 24

H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively

H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...
Narrative Update • May 23

HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside

Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.
Analysis Article • May 15

Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Narrative Update • May 05

HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins

Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.
Narrative Update • Apr 20

HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook

Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.
Narrative Update • Apr 05

HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins

Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.
Narrative Update • Mar 22

HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion

Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.
Narrative Update • Mar 08

HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential

Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.
Narrative Update • Feb 22

HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook

Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.
Narrative Update • Feb 08

HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares

Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.
Analysis Article • Feb 07

H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...
Narrative Update • Jan 25

HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook

Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.
Analysis Article • Jan 14

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Narrative Update • Jan 11

HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook

Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.
Narrative Update • Dec 27

HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements

Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.
Narrative Update • Dec 13

HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares

Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.
Analysis Article • Nov 22

The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business

H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...
Analysis Article • Nov 15

Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...
Analysis Article • Oct 28

Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)

With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...
Narrative Update • Sep 05

CNS Pipeline And Global Expansion Will Unlock Future Opportunities

With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.
Analysis Article • Aug 16

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...
User avatar
New Narrative • Dec 04

Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth

Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.

Earnings and Revenue Growth Forecasts

CPSE:HLUN B - Analysts future estimates and past financials data (DKK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202824,9604,6655,5926,03710
12/31/202725,7354,8076,2446,72811
12/31/202625,7044,7105,6166,24711
3/31/202625,5203,7304,8255,448N/A
12/31/202524,6303,1924,8635,481N/A
9/30/202524,0783,7772,7783,406N/A
6/30/202523,5213,4532,8513,409N/A
3/31/202522,9513,2572,4152,997N/A
12/31/202422,0043,1432,7613,326N/A
9/30/202421,4412,6874,9365,421N/A
6/30/202420,6712,5864,1284,609N/A
3/31/202420,1562,4164,1454,663N/A
12/31/202319,9122,2903,5794,080N/A
9/30/202319,6142,4673,5284,426N/A
6/30/202319,3812,4793,5234,457N/A
3/31/202318,9182,3843,2924,102N/A
12/31/202218,2461,9162,6993,519N/A
9/30/202217,6191,6032,0512,615N/A
6/30/202216,9131,2361,7442,313N/A
3/31/202216,3981,1091,3441,959N/A
12/31/202116,2991,3181,6602,272N/A
9/30/202116,5211,8732,4052,949N/A
6/30/202116,9711,9652,3792,912N/A
3/31/202117,3812,1103,2633,757N/A
12/31/202017,6721,5813,3593,837N/A
9/30/202017,8189042,7133,171N/A
6/30/202017,4901,2422,9103,354N/A
3/31/202017,3661,5071,5021,960N/A
12/31/201917,0362,313N/A2,609N/A
9/30/201916,8113,091N/A3,621N/A
6/30/201917,3093,395N/A3,462N/A
3/31/201917,7663,606N/A4,815N/A
12/31/201818,1173,907N/A5,981N/A
9/30/201818,3133,806N/A5,922N/A
6/30/201818,0283,627N/A6,197N/A
3/31/201817,6083,236N/A5,397N/A
12/31/201717,2342,624N/A4,045N/A
9/30/201717,0072,544N/A3,731N/A
6/30/201716,6071,988N/A3,551N/A
3/31/201716,0751,612N/A3,420N/A
12/31/201615,6341,211N/A3,126N/A
9/30/201615,202290N/A4,158N/A
6/30/201614,923-1,289N/A2,755N/A
3/31/201614,801-5,427N/A936N/A
12/31/201514,594-5,694N/A197N/A
9/30/201514,108-5,879N/A-1,330N/A
6/30/201513,625-4,615N/A-464N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLUN B's earnings are forecast to decline over the next 3 years (-4.5% per year).

Earnings vs Market: HLUN B's earnings are forecast to decline over the next 3 years (-4.5% per year).

High Growth Earnings: HLUN B's earnings are forecast to decline over the next 3 years.

Revenue vs Market: HLUN B's revenue is expected to decline over the next 3 years (-3.4% per year).

High Growth Revenue: HLUN B's revenue is forecast to decline over the next 3 years (-3.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HLUN B's Return on Equity is forecast to be low in 3 years time (12.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 13:12
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 33 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily FieldBarclays
Charles PitmanBarclays
Rosie TurnerBarclays